Chicago's Piping plovers Imani and Sea Rocket lay first egg of season
Piping plovers Imani and Sea Rocket lay first egg of season
Piping plovers Imani and Sea Rocket lay first egg of season
Piping plovers Imani and Sea Rocket lay first egg of season
The next generation of Montrose Beach's piping plovers are to be on the way.
Chicago's beloved Imani and Sea Rocket laid their first egg of the season on the Montrose Beach dunes shoreline Sunday morning.
Volunteers said they expect Sea Rocket to lay four eggs total.
Along with Imani and Sea Rocket, volunteers said Pippin is also back at Montrose Beach for the season.
It is now peak of migration season.
The Montrose Point Bird Sanctuary attracts tens of thousands of migratory birds every year. It features a Magic Hedge — a 150-yard stretch of shrubs and trees — that attracts an especially large number of species. Piping plovers are found not in the Magic Hedge, but on the beach.
Monty and Rose — named after the beach that is in turn named after the east-west street of which it serves at the mouth — were the first to nest at Montrose Beach in 71 years when they appeared in 2019.
Pippin was hatched in 2023 in Cat Island — located in Lake Superior in the northernmost reaches of Wisconsin.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
14 minutes ago
- Medscape
ADA Issues New MASLD Guidelines
A new consensus report from the American Diabetes Association (ADA) provides a practice-oriented framework for screening and managing metabolic dysfunction–associated steatotic liver disease (MASLD) in people with diabetes and prediabetes. Published online on May 28, 2025, in Diabetes Care, the report is a comprehensive update to the recommendations the ADA released in 2023. It is intended for clinicians treating patients with diabetes — primarily type 2 diabetes (T2D) — but also type 1 diabetes with obesity and prediabetes. Topics covered include the rationale for the recent change in terminology, epidemiology, fibrosis risk stratification, monitoring, treatment, and referral guidance, with interprofessional team management emphasized throughout. 'This will provide primary care doctors and anyone taking care of people with diabetes the tools to diagnose [MASLD] early and guide therapy…to prevent cirrhosis, and refer to the hepatologist as needed for additional therapy and monitoring,' lead author Kenneth Cusi, MD, professor of medicine at the Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida, Gainesville, Florida, told Medscape Medical News . The guidelines recommend that clinicians routinely screen people with T2D or prediabetes for MASLD. 'We explain that the liver should be incorporated into our management in the same way we do for chronic kidney disease, eye disease, and nerve disease as an end-organ damage that is particularly affected by diabetes,' Cusi said. In the United States, at least 70% of people with T2D have MASLD, about half of whom have the more progressive form termed metabolic dysfunction–associated steatohepatitis (MASH). About 1 in 5 with T2D have advanced liver fibrosis. The presence of MASH increases the risks for complications including cirrhosis, hepatocellular carcinoma, and overall mortality, according to the new consensus report. Liver disease has not been a focus of diabetes management until recently, Cusi noted. 'We didn't think about it. The epidemic of obesity, and with that, of diabetes, is driving this liver disease. The obesity epidemic has had a big worsening since the 1990s, so this damage in the past 20 or 30 years is just now becoming evident in the liver.' Terminology Change: Highlighting Insulin Resistance, Reducing Stigma The document reviews the current nomenclature for SLD, which was officially changed in 2023 to remove the words 'fatty' and 'alcoholic.' Now, MASLD is defined as the presence of SLD with at least one metabolic risk factor such as obesity, hypertension, prediabetes, high triglycerides, low high-density lipoprotein cholesterol, or T2D, with minimal or no alcohol consumption (< 20 g/d for women; < 30 g/d for men). The term 'MetALD' is used for those with MASLD who also have increased alcohol consumption (20-50 g/d for women; 30-60 g/day for men). Steatosis in the setting of alcohol consumption above those levels is termed 'alcohol-associated liver disease (ALD).' The term MASH is defined as steatohepatitis with at least one metabolic risk factor and minimal alcohol consumption. 'At-risk MASH' refers to steatohepatitis with clinically significant fibrosis (stage F2 or higher). Diagnosis: Staged Screening for Fibrosis The document recommends routine screening of people with T2D, prediabetes, and/or obesity with cardiovascular risk factors, with the goal of identifying those with high-risk MASH. Intervention is then aimed at preventing fibrosis progression and cirrhosis. A graphic diagnostic algorithm advises initial use of the noninvasive Fibrosis-4 (FIB-4) tool, which risk stratifies based on age, liver enzymes, and platelet count. 'The FIB-4 is composed of very simple things that are already in the electronic medical record of all patients. We also discuss the role of electronic medical records to improve implementation,' Cusi said. Those with a FIB-4 < 1.3 have a low risk for future cirrhosis and can be managed in primary or team care with optimized lifestyle and repeated FIB-4 every 1-2 years. If the FIB-4 is > 2.67, direct referral to a liver specialist is advised. If FIB-4 is between 1.3 and 2.67, a second risk-stratification test is recommended. Ideally, this would be a liver stiffness measurement (LSM), most commonly with transient elastography. If that is unavailable, an alternative is the noninvasive enhanced liver fibrosis (ELF) test. If the LSM is < 8.0 kPa or ELF is < 7.7, the fibrosis risk is low and routine management can continue with repeat testing in 1-2 years. But if higher, hepatology referral is recommended. Treatment: Lifestyle, Plus Old and New Drugs The report details lifestyle modification for MASLD, including nutrition plans; physical activity; behavioral health; and the role of diabetes self-management, education and support. The role of obesity treatment in people with MASLD, both metabolic surgery and pharmacotherapy, is also discussed at length. No current pharmacologic treatments have been approved for MASLD, but both semaglutide and tirzepatide have demonstrated benefit in treating MASH and are approved for treating T2D, obesity, and other related comorbidities. A thyroid hormone receptor beta agonist, resmetirom, was approved in early 2024 for the treatment of MASH with fibrosis stages F2 and F3, but is extremely expensive at about $50,000 a year, Cusi noted. An older, generic glucose-lowering drug, pioglitazone, has also shown benefit in reducing fibrosis and may be a lower-cost alternative. The document also includes a section on alcohol intake, which complicates the MASLD picture, Cusi noted. 'We think that this is going to help doctors to consider alcohol, which is often overlooked and under-reported. If patients have moderate fibrosis, they should completely quit alcohol.' Cusi has received research support (to his institution) from Boehringer Ingelheim, Echosens, Inventiva, Labcorp, and Perspectum, and has served as a consultant for Aligos Therapeutics, Arrowhead, AstraZeneca, 89bio, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Novo Nordisk, ProSciento, Sagimet Biosciences, Siemens USA, Zealand Pharma, and Terns Pharmaceuticals.
New York Times
an hour ago
- New York Times
Scientific Discoveries, and Dreams, in the Balance
One of the joys of science journalism is in seeing dreams come true — watching scientists push their career chips across the table, on behalf of a vision or a mission that will take years to achieve, and finally win. Their stories are sagas of passion, curiosity and sacrifice. William Borucki, a space scientist who didn't have a Ph.D., and his collaborator, David Koch, spent 20 years trying to convince NASA that a space telescope could find planets by detecting their shadows on other stars. NASA rejected their proposal five times until ultimately relenting. 'It's a wonderful thing to have someone tell you over and over again everything that is wrong with your experiment,' Mr. Borucki once said. He changed the galaxy: The Kepler satellite, launched in 2009, discovered more than 4,000 exoplanets in a small patch of the Milky Way, suggesting that there were as many as 40 billion potentially habitable planets in the Milky Way alone. Scientists involved in the effort to detect the space-time ripples known as gravitational waves tell a similar story. In the 1970s and 80s, when Rainer Weiss, a physicist at M.I.T., and Kip Thorne of Caltech started talking to the National Science Foundation about the possibility of observing these waves, 'everybody thought we were out of our minds,' Dr. Weiss once said. Want all of The Times? Subscribe.
Washington Post
an hour ago
- Washington Post
Coastal communities are flooding more than we realize. Here's why.
Fast-rising seas have forced some coastal communities to endure flooding far more frequently than previously thought, and much more often than federal tide gauges would suggest, according to a new findings from researchers in North Carolina. 'I view it as a harbinger of what's to come,' said Katherine Anarde, an assistant professor of coastal engineering at North Carolina State University and one of the lead authors of the study, published Monday in the journal Communications Earth & Environment.
